Menopause & Hormone Replacement Therapy

Overview & Definition

Menopause is high-yield for one reason: it sits at the intersection of endocrine physiology (the follicle-depleted ovary), symptom management (the most common reason a middle-aged woman sees her doctor), a risk-benefit drug decision (HRT), and a red-flag referral rule (postmenopausal bleeding). Every examiner has a question on the timing hypothesis, the progestogen-for-the-uterus rule, or the work-up of PMB, because each tests whether a candidate can reason rather than recite. [1]

Definition. Menopause is the permanent cessation of menstruation, defined retrospectively as 12 consecutive months of amenorrhoea in a woman of the expected age, in the absence of any other pathological or physiological cause.[1] The average age is 50 to 52 years in most populations; the accepted normal range is 45 to 55. The years flanking the final menstrual period — when endocrine, biological and clinical features of approaching menopause begin — are the menopausal transition (perimenopause), ending 12 months after the last period.[1][5]

The key concept is that menopause is a diagnosis of follicle depletion. A female fetus carries 6 to 7 million oogonia; by birth about 1 to 2 million; by menarche 300,000 to 500,000; and by the menopause fewer than 1000 follicles remain. When the follicle reserve can no longer produce enough oestradiol to drive cyclic endometrial growth, menses cease.[1]

[8] [11] [12]

[1] [7]

Classification

Menopause is classified by distance from the final menstrual period and by cause, both of which drive management. The most clinically useful framework is the STRAW +10 (Stages of Reproductive Aging Workshop) staging system, which anchors every other discussion.[7]

[1] [7]

The STRAW +10 revisions simplified the bleeding criteria that define the early and late menopausal transition, refined the late-reproductive and early-postmenopause stages, characterised the duration of the late transition and the early postmenopause, and were designed to apply regardless of age, ethnicity, body size or lifestyle.[7] The staging is anchored to endocrine and ovarian markers — antimüllerian hormone and inhibin B decline while follicle-stimulating hormone rises, paralleling the fall in antral follicle count.[7]

[1] [7] [8] [9]

Epidemiology & Risk Factors

Menopause is universal in women who live long enough, but its timing and severity vary. About 75 percent of perimenopausal and postmenopausal women experience vasomotor symptoms, and over 25 percent describe them as severe.[1] Symptoms last an average of 7 years and persist for over a decade in 10 to 15 percent — a fact that refutes the common misconception that "it lasts a year or two".

POI affects about 1 percent of women under 40 and 0.1 percent under 30. Risk factors for an earlier menopause include smoking (brings menopause forward by 1 to 2 years through accelerated follicle atresia), nulliparity, family history of early menopause, autoimmune disease, and iatrogenic causes (chemotherapy, pelvic radiotherapy, bilateral oophorectomy). Risk factors for more severe vasomotor symptoms include obesity (insulation theory plus altered thermoregulation), smoking, anxiety and depression, low socioeconomic status, and sedentary lifestyle.[1]

Pathophysiology

The mechanism of menopause is a loss of negative feedback. The transition is characterised by the gradual loss of oocytes, altered responsiveness to gonadal steroid feedback, wide hormonal fluctuations and irregular menstrual patterns.[1] The cohort data underpinning STRAW +10 tracked the endocrine markers of reproductive aging — antimüllerian hormone and inhibin B decline while FSH rises across the stages, so a persistently raised FSH is the biochemical signature of the follicle-depleted ovary.[7]

The perimenopause is hormonally paradoxical: oestradiol fluctuates wildly (sometimes to supranormal levels because the high FSH over-drives the remaining follicles each cycle), while inhibin B is low and cycles become anovulatory. This explains the heavy, irregular bleeding of the transition and the unpredictability of symptoms — a woman can have severe hot flushes one week and breast tenderness the next. [1]

[1]

The GnRH pulse generator: KNDy neurons

At the centre of the HPO axis sits the GnRH pulse generator — a population of kisspeptin, neurokinin B and dynorphin (KNDy) neurons in the hypothalamic arcuate nucleus. Kisspeptin is the most potent upstream activator of GnRH neurons known; neurokinin B stimulates pulse frequency while dynorphin provides the off-switch that sculpts each pulse. In the menopause, loss of oestradiol and inhibin negative feedback on KNDy neurons produces high-amplitude, high-frequency GnRH pulses, which in turn drive the disproportionately high FSH that is the biochemical signature. This is why FSH rises before LH in the transition (FSH is more pulse-frequency-sensitive than LH) and why an elevated FSH can be detected years before the final menstrual period while cycles are still regular.[1]

Folliculogenesis and the marker of ovarian reserve

Follicular development is a continuous process that begins in fetal life and does not pause. Primordial follicles are recruited continuously into the growing pool; each cycle, a cohort is recruited and a single dominant follicle is selected. Anti-Müllerian hormone (AMH), produced by the granulosa cells of small growing follicles, is the best quantitative marker of ovarian reserve. AMH falls progressively throughout reproductive life and becomes undetectable as the menopause approaches — it typically declines before FSH rises, making it the earliest indicator of declining reserve. In clinical practice AMH is not needed to diagnose natural menopause (it is a clinical diagnosis over the age of 45), but it is useful in fertility assessment, in the work-up of POI, and to predict the menopausal transition in women undergoing chemotherapy. Inhibin B is produced by the dominant follicle and corpus luteum and selectively suppresses FSH; its loss in the transition is the reason FSH climbs. [1]

The hot flush — the thermoneutral zone model

The modern mechanistic explanation of the hot flush is the thermoneutral zone model (Freedman). Core body temperature is normally defended within a narrow zone (about 0.4 degrees Celsius) between the thresholds for sweating (heat loss) and shivering (heat generation). Oestradiol normally widens this zone. In oestrogen deficiency the zone narrows markedly, so even a tiny upward drift in core temperature — from a warm room, a hot drink, stress, or the normal pre-ovulatory or nocturnal rise — triggers an exaggerated heat-dissipation response: a sudden surge of cutaneous vasodilation (especially of the face, neck and upper chest, producing the visible flush), profuse sweating, and a reflex tachycardia with a transient fall in blood pressure. The patient then perceives an overshoot chill as the temperature drops below the narrowed zone. The neuronal pathway involves noradrenergic projections from the brainstem and the KNDy neurons in the arcuate nucleus, which explains why neuroactive drugs (SSRIs, SNRIs, gabapentin, clonidine) can dampen flushes without replacing oestrogen. [1]

Bone loss — the RANKL / osteoprotegerin axis

Bone is remodelled continuously in coupled units of osteoclast-mediated resorption followed by osteoblast-mediated formation. The master switch of osteoclastogenesis is RANKL (Receptor Activator of Nuclear factor kappa-B Ligand), expressed by osteoblasts and marrow stromal cells; it binds the RANK receptor on osteoclast precursors and drives their maturation and activation. Osteoprotegerin (OPG) is a soluble decoy receptor that mops up RANKL and inhibits osteoclastogenesis. Oestrogen normally upregulates OPG and downregulates RANKL, restraining resorption and promoting osteoblast survival. Loss of oestrogen removes this restraint: RANKL rises, OPG falls, osteoclasts over-activate, and each remodelling cycle removes slightly more bone than is replaced. The result is high-turnover bone loss — about 10 percent of cortical and up to 15 to 20 percent of trabecular bone over the first five years after menopause, with vertebral (trabecular) bone lost earliest and fastest. This is also why denosumab (a monoclonal anti-RANKL antibody) and oestrogen both work for postmenopausal osteoporosis — they target the same final common pathway. [1]

Genitourinary atrophy — histology and microbiome

The vulva, vagina and lower urinary tract are rich in oestrogen receptors. In reproductive life the vaginal epithelium is a thick, stratified squamous epithelium rich in glycogen (deposited under oestrogen stimulation). Lactobacilli metabolise glycogen to lactic acid, maintaining a vaginal pH of 3.8 to 4.5 that inhibits pathogens. In oestrogen deficiency the epithelium thins to a few parabasal cell layers, glycogen is lost, lactobacilli disappear, and the vaginal pH rises above 5 — producing the characteristic vaginal maturation index shift (parabasal cells predominate, intermediate and superficial cells vanish). The tissue becomes pale, thin, dry and fragile, with loss of rugae and elasticity; the urethra and bladder trigone, which share the same embryological origin, undergo parallel atrophy — explaining the dyspareunia, recurrent UTI, urgency and incontinence of the genitourinary syndrome of menopause, and why low-dose vaginal oestradiol reverses these changes locally with negligible systemic absorption. [1]

Cardiovascular consequences

Oestrogen has multiple favourable cardiovascular effects: it improves the lipid profile (lower LDL and total cholesterol, higher HDL — though also a small rise in triglycerides with oral therapy), enhances endothelial function via nitric oxide and prostacyclin, supports endothelial progenitor cell mobilisation, and is anti-atherogenic. Loss of oestrogen around the menopause coincides with the postmenopausal acceleration of atherosclerosis and the rising cardiovascular event rate in women in their 50s and 60s. This biological substrate underlies the 'timing hypothesis' — replacing oestrogen early, before established plaque, may be protective, while giving it late, to a woman with established atherosclerosis, can destabilise plaque and precipitate events (the WHI cardiovascular signal in older starters). [1]

Clinical Presentation

The menopausal presentation clusters into four symptom domains, each with a specific mechanism and treatment. A candidate who can name all four and their temporal order has answered most of the clinical viva before it is asked.[1]

Vasomotor symptoms are the hallmark. A hot flush is a sudden, intense sensation of heat over the face, neck and chest, lasting 1 to 5 minutes, accompanied by flushing, sweating, palpitations and occasionally a follow-on chill. Flushes are worse at night (then called night sweats), with heat, stress, spicy food, caffeine and alcohol. They disrupt sleep, which in turn drives the fatigue, low mood and cognitive "brain fog" of the transition. [1]

Genitourinary syndrome of menopause (GSM) is the modern term for vulvovaginal and lower-urinary-tract atrophy. Symptoms include vaginal dryness, itching, burning, dyspareunia, postcoital bleeding, and urinary urgency, dysuria, recurrent UTI and incontinence. Unlike vasomotor symptoms, GSM tends to worsen without treatment and rarely remits spontaneously. [1]

Psychological and sleep symptoms — mood swings, irritability, low mood, anxiety, sleep disturbance with early-morning waking, and the subjective cognitive "brain fog" of poor concentration. The mood change is partly direct (oestrogen modulates serotonin and noradrenaline) and partly the consequence of sleep disruption from night sweats. [1]

Menstrual change in the perimenopause — cycles initially shorten (short follicular phase), then lengthen and vary, flow becomes variable, cycles are anovulatory, and ultimately menses cease. Heavy, irregular bleeding in the transition must always prompt consideration of endometrial pathology. [1]

Long-term somatic consequences of unrecognised or untreated oestrogen deficiency — osteopenia and osteoporosis (with height loss, kyphosis and fragility fracture), urogenital atrophy, skin thinning and breast atrophy, central fat redistribution, and a rising cardiovascular risk profile. [1]

The temporal sequence — what comes first

Symptoms do not arrive all at once, and recognising the sequence helps distinguish the transition from mimics. The earliest endocrine change is a rise in FSH with a shortening of the follicular phase (cycles become shorter, often 21 to 24 days) and heavier flow — sometimes years before any vasomotor symptom. Vasomotor symptoms typically begin in late perimenopause and peak in the first one to two years postmenopause, then gradually fade. The genitourinary syndrome usually becomes clinically significant later — often years into the postmenopause, as oestrogen-dependent tissues slowly atrophy — and, unlike vasomotor symptoms, progresses without treatment. Mood and cognitive symptoms cluster with the vasomotor phase, while bone and cardiovascular consequences accumulate silently over decades. [1]

Quantifying the symptoms

Two validated instruments are widely used. The Menopause Rating Scale (MRS) scores eleven symptoms across somatic, psychological and urogenital domains and is useful for baseline and follow-up. The Greene Climacteric Scale similarly quantifies vasomotor, psychological and somatic symptoms. In practice the decision to treat is clinical — a woman whose vasomotor symptoms disrupt her sleep, work or relationships warrants treatment regardless of the score. [1]

Sleep architecture and the "brain fog"

Sleep disturbance in the transition is partly direct (oestrogen modulates sleep architecture, reducing slow-wave sleep) and partly the consequence of night sweats that fragment sleep with frequent awakenings. The resulting sleep deprivation drives the daytime fatigue, irritability, poor concentration and subjective "brain fog" — symptoms that overlap with, but are mechanistically distinct from, a primary depressive disorder. Restoring sleep (with HRT, with CBT, or with gabapentin when night sweats dominate) often resolves the cognitive symptoms without an antidepressant. [1]

The genitourinary syndrome — the symptom that progresses

The genitourinary syndrome of menopause is often under-recognised because women are reluctant to volunteer sexual symptoms and clinicians do not routinely ask. The progression is predictable: vaginal dryness and itching appear first, then dyspareunia (entry dyspareunia from introital narrowing and loss of distensibility), then postcoital bleeding from fragile atrophic epithelium, then recurrent urinary tract infection and urgency / incontinence as the lower urinary tract atrophies. Untreated, the vagina can shorten and narrow, producing a functional vaginal stenosis that makes pelvic examination — and sexual intercourse — painful or impossible. The early use of low-dose vaginal oestrogen can prevent this progression. [1]

Differential Diagnosis

Menopause is usually obvious, but its individual symptoms are not. The differentials below are the ones examiners probe. [1]

Differential of hot flushes — hyperthyroidism (weight loss, tremor, heat intolerance, tachycardia), carcinoid syndrome (diarrhoea, wheeze, flushing, valvular disease), phaeochromocytoma (paroxysmal hypertension, headache, palpitation), infection (fever pattern), anxiety / panic disorder (psychological trigger, dyspnoea, paraesthesia), and drug-related (niacin, calcium-channel blockers, tamoxifen, GnRH analogues, steroids).[1]

Differential of postmenopausal bleeding (PMB), ranked by urgency — endometrial cancer (always exclude first), endometrial hyperplasia, atrophic vaginitis / GSM, cervical cancer, endometrial / cervical polyp, HRT-related withdrawal, and rarely oestrogen-secreting ovarian tumour (granulosa-cell). About 5 to 10 percent of women with PMB have endometrial cancer; the rate rises with age and risk factors. [1]

Differential of low mood in the transition — menopausal mood disturbance, major depressive disorder, thyroid dysfunction, adjustment disorder, anxiety disorder, and substance misuse. Distinguish by timing (worse in the late transition), prior psychiatric history, persistence independent of vasomotor symptoms, and the cardinal features of depression (anhedonia, suicidal ideation). [1]

Clinical & Bedside Assessment

The focused history captures the symptom cluster, the impact on life, the contraindications to HRT, and the risk factors for osteoporosis and cardiovascular disease. Ask about age, menstrual pattern, vasomotor, genitourinary, mood, sleep, libido, lifestyle (smoking, alcohol, exercise, diet), drug history (OCP, prior HRT, tamoxifen), and a personal and family history of breast cancer, VTE, stroke, cardiovascular disease and osteoporosis.[5]

Examination should include BMI, blood pressure, breast examination, abdominal and pelvic examination (speculum to assess vaginal atrophy, cervical status and any bleeding source; bimanual for uterine size, masses and tenderness), and a search for signs of thyroid disease and anaemia. The genitourinary syndrome can be quantified at the bedside by vaginal inspection (thinning, pallor, loss of rugae, dryness, petechiae) and a vaginal pH over 5. [1]

Absolute contraindications to systemic oestrogen that must be actively sought at every consult: current or past breast cancer, oestrogen-sensitive cancer, active liver disease, personal history of VTE or ischaemic stroke, unexplained vaginal bleeding until investigated, and pregnancy.[2][5]

Absolute versus relative contraindications — the viva distinction

Examiners distinguish absolute from relative contraindications because the response differs: an absolute contraindication means no systemic oestrogen at all (use non-hormonal options); a relative contraindication means modify the regimen (typically switch to transdermal and seek specialist input). [1]

Investigations

Menopause is a clinical diagnosis in a woman over 45 with typical symptoms — no routine blood tests are required.[5] Investigations are reserved for specific indications.

[13]

Tests before starting HRT — blood pressure, BMI, breast awareness (and mammography per the national screening programme), lipid and glucose profile if risk factors, and a baseline DEXA if osteoporosis risk factors are present. [1]

Investigating postmenopausal bleeding — transvaginal ultrasound first: an endometrial thickness over 4 to 5 mm warrants biopsy. Perform out-patient endometrial biopsy (Pipelle); if sampling is inadequate or bleeding is recurrent, proceed to hysteroscopy with targeted biopsy. Always also inspect the cervix (exclude cervical cancer) and vagina (exclude atrophic or neoplastic causes). [1]

Work-up of POI after a raised FSH is confirmed — karyotype, fragile X (FMR1) premutation screen, adrenal (21-hydroxylase) and thyroid antibodies, pelvic ultrasound (autoimmune oophoritis, follicles), and a baseline DEXA.[1]

DEXA in the menopausal woman — screening with dual-energy x-ray absorptiometry should be considered for all women 65 years and older and for postmenopausal women with clinical risk factors; osteoporosis is diagnosed at a T-score of −2.5 or less or by the presence of a fragility fracture.[18] Guideline care then stratifies the patient into high-risk and very-high-risk categories to select and sequence therapy.[19]

Interpreting the hormone panel — patterns at a glance

When a woman of menopausal age presents with amenorrhoea, a systematic evaluation — detailed history, physical examination and selected serum hormone levels — usually identifies the underlying cause; the pattern across the initial panel is more informative than any single value. [13]

[13]

Structured evaluation of amenorrhoea

Secondary amenorrhoea is the cessation of regular menses for three months (or of irregular menses for six months); most cases are attributable to polycystic ovary syndrome, hypothalamic amenorrhoea, hyperprolactinaemia or primary ovarian insufficiency, and pregnancy should be excluded in all cases before any hormonal interpretation.[13] Patients with hypothalamic amenorrhoea should be evaluated for eating disorders and are at risk of decreased bone density; patients with POI can maintain unpredictable ovarian function and should not be presumed infertile.[13]

Management — Resuscitation & Immediate

There is no resuscitation in the usual sense, but a small set of presentations need urgent referral or escalation and must not be managed routinely: [1]

• Suspected endometrial pathology — women 35 years or older with recurrent anovulation, younger women with risk factors for endometrial cancer, and excessive bleeding unresponsive to medical therapy should undergo endometrial biopsy; findings of hyperplasia with atypia or adenocarcinoma are referred to a gynaecologist or gynaecologic oncologist.[14]
• Mood disturbance in the transition — the menopausal transition precipitates mood disruption; distinguish and treat a primary depressive disorder on its own merits.[1]
• Suspected VTE or stroke on HRT — stroke and venous thromboembolism are characterised risks of HRT; stop systemic therapy, investigate and involve haematology.[2]
• Heavy irregular perimenopausal bleeding — first exclude pregnancy and endometrial pathology;[14] effective medical options include the levonorgestrel-releasing intrauterine system, oral progesterone for 21 days per month, nonsteroidal anti-inflammatory drugs, and tranexamic acid (approved for ovulatory heavy bleeding); combination oral contraceptives or progestins regulate cycles.[14]

Management — Definitive & Stepwise

Treatment is individualised — the right patient, right agent, right route, right timing. The four pillars are lifestyle for all, HRT when indicated, non-hormonal options when HRT is contraindicated, and bone-protective therapy. [1]

1. Lifestyle measures (every woman)

Weight-bearing and aerobic exercise (bone, cardiovascular, mood, weight), smoking cessation (reduces flushes, protects bone, lowers cardiovascular risk, may delay menopause), moderation of alcohol and caffeine (reduce vasomotor triggers), a healthy diet rich in calcium and vitamin D, sleep hygiene, layered clothing and fans, and weight management. Cognitive behavioural therapy (CBT) has evidence for vasomotor and mood symptoms.[1]

2. Hormone replacement therapy (HRT)

HRT is the most effective treatment for vasomotor symptoms (over 75 percent reduction), for GSM and for bone protection, and is indicated for symptomatic women under 60 or within 10 years of menopause with no contraindication.[3][5]

Oestrogen — oral (conjugated equine oestrogen, oestradiol valerate; convenient but higher VTE/stroke risk), transdermal (patch or gel — preferred when VTE risk, migraine with aura, obesity, hypertriglyceridaemia, gallstones, smoking over 35), vaginal (low-dose oestradiol cream or tablets — for GSM only, minimal systemic absorption). [1]

Progestogen — for a woman with an intact uterus, systemic oestrogen must be combined with a progestogen (or bazedoxifene) to protect the endometrium.[2] In PEPI, all three combined regimens — CEE 0.625 mg plus cyclic micronised progesterone 200 mg for the first 12 days of each 28-day cycle, CEE plus cyclic MPA 10 mg, and CEE plus continuous MPA 2.5 mg — held hyperplasia at placebo-level rates, whereas unopposed CEE caused hyperplasia in 27.7% at 3 years.[11] In the French E3N cohort, breast-cancer risk varied by progestogen: oestrogen plus progesterone RR 1.00, plus dydrogesterone RR 1.16, plus other progestagens RR 1.69 vs never-use, with no difference by oestrogen route — favouring progesterone or dydrogesterone.[17] Medroxyprogesterone acetate was the WHI trial progestin.[3] The levonorgestrel IUS is an effective alternative in heavy bleeding.[14]

Regimens — cyclical / sequential for the perimenopause and within 1 to 2 years of the last period (continuous oestrogen with a progestogen for 12 to 14 days each month → a regular withdrawal bleed). Continuous combined for postmenopausal women more than 1 to 2 years past the last period (daily oestrogen plus progestogen → bleed-free after a few months). [1]

Tibolone — at 2.5 mg daily, tibolone increased lumbar-spine and femoral-neck bone mineral density versus non-active controls in postmenopausal women, with no difference from oestrogen therapy, and reduced vasomotor-symptom severity in a network meta-analysis.[16][24]

3. Vaginal oestrogen for isolated GSM

For bothersome genitourinary syndrome of menopause not relieved with over-the-counter therapies in women without indications for systemic hormone therapy, low-dose vaginal oestrogen is recommended — with vaginal dehydroepiandrosterone and oral ospemifene as alternatives.[5] Vulvovaginal atrophy affects close to half of postmenopausal women, and 10 to 20 percent of women taking systemic oestrogen still have residual symptoms — so vaginal therapy may be added alongside systemic HRT.[12]

4. Non-hormonal options for vasomotor symptoms

For women in whom systemic oestrogen is contraindicated or declined: [1]

[15] [24] [25]

5. Bone protection

All patients with osteoporosis should be counselled on weight-bearing exercise, smoking cessation, moderation of alcohol intake, and calcium and vitamin D supplementation.[18] Treatment is guided by fracture risk: patients at high risk should consider antiresorptive therapy — bisphosphonates or denosumab; patients at very high risk or with previous vertebral fractures should consider anabolic agents — teriparatide, abaloparatide or romosozumab.[18] Hormone therapy itself has been shown to prevent bone loss and fracture in postmenopausal women.[5] [19]

6. Testosterone for hypoactive sexual desire disorder

Systemic transdermal testosterone may be offered to a postmenopausal woman with hypoactive sexual desire disorder (HSDD) not primarily related to modifiable factors or comorbidities; current evidence supports a moderate therapeutic benefit.[20] Government-approved transdermal male formulations can be used cautiously with dosing appropriate for women; patients should be assessed for signs of androgen excess and total testosterone monitored to maintain concentrations in the physiologic premenopausal range; compounded products cannot be recommended.[20]

7. HRT pharmacology reference — every agent, every dose

The single most common reason a candidate loses marks on a menopause viva is a vague answer about HRT doses. The table below collects the regimens as tested in the landmark trials and cohort evidence: the oestrogen, the progestogen, and what each source showed. [3][11]

[3] [11] [16] [17] [20] [23] [24] [14]

Dose, route and duration. The risks of hormone therapy differ depending on type, dose, duration of use, route of administration, timing of initiation, and whether a progestogen is used, so treatment is individualised with periodic re-evaluation of the benefit-risk balance.[5] Prescribing nuances include cyclic versus continuous administration and tapering of therapy.[2]

Trigger points

• Start at 3 months: review symptom control and side-effects, titrate dose.
• Annual review: blood pressure, weight, breast awareness, assess ongoing need; the aim is the lowest effective dose for the shortest necessary time — but there is no mandatory time limit and duration is individualised.
• Stop when symptoms have resolved (typically 2 to 5 years); taper or stop abruptly — there is no safety requirement to wean, though tapering reduces symptom rebound.
• Urgent review for any unscheduled or postmenopausal bleeding, chest pain, calf pain or swelling, breathlessness, or a sudden severe headache. [1]

Managing common HRT side-effects

Side-effects are common in the first weeks to months of HRT and usually settle as the body equilibrates. A structured approach prevents premature discontinuation (the commonest reason HRT "fails"). [1]

Unscheduled bleeding on HRT — the algorithm

Unscheduled bleeding on HRT is the single most common reason a candidate must demonstrate a structured answer. The principle is identical to that for postmenopausal bleeding: never assume it is the drug. [1]

1. When does bleeding count as "unscheduled"? On a cyclical regimen, any bleeding outside the expected progestogen-withdrawal window. On continuous combined therapy, any bleeding after the first 6 months (light irregular spotting in the first 3 to 6 months is common and acceptable). [1]

2. What to do. (i) Examine — speculum (cervical/vaginal cause, atrophy, polyp) and bimanual (uterine size, tenderness). (ii) Transvaginal ultrasound — measure endometrial thickness. (iii) If the endometrial thickness is over 4 to 5 mm, perform out-patient endometrial biopsy (Pipelle). (iv) If sampling is inadequate, bleeding is recurrent, or the ultrasound is suspicious, proceed to hysteroscopy with targeted biopsy. [1]

3. If pathology is excluded and bleeding persists, increase the progestogen duration (e.g. from 12 to 14 days in a cyclical regimen) or switch the progestogen (to micronised progesterone or the levonorgestrel IUS); consider switching from continuous combined to a cyclical regimen if the woman is actually still perimenopausal.[5]

Contraception and the perimenopause — the often-missed rule

HRT does not suppress ovulation, and a perimenopausal woman can still conceive. Continue a separate contraceptive method until she is definitively postmenopausal: two years of amenorrhoea before age 50, or one year of amenorrhoea after age 50. The combined oral contraceptive pill can be used off-label until age 50 in non-smokers without contraindications (it both controls cycle irregularity and provides vasomotor relief); the levonorgestrel IUS (Mirena) is an excellent dual-purpose option that also provides the progestogen component of HRT. Sterilisation and barrier methods remain valid throughout. Fertility declines sharply in the late transition but is never zero until the menopause is confirmed.[5]

Specific Subtypes & Scenarios

• Premature ovarian insufficiency (under 40) — loss of ovarian activity before age 40 with irregular or absent periods and reduced fertility; oestrogen deficiency drives osteoporosis and cardiovascular disease and a shorter life expectancy. HRT is strongly recommended — mainly for vasomotor and genito-urinary symptom relief, with a role in bone protection and probable primary prevention of cardiovascular disease; the controversies that surround postmenopausal HRT do not apply.[9]
• Diagnosis and monitoring in POI — the ESHRE guideline devotes recommendations to diagnosis and assessment, the sequelae of POI and their monitoring, and HRT, including puberty induction.[10]
• Woman with a uterus versus hysterectomised — in WHI, women with an intact uterus received CEE plus MPA while women with prior hysterectomy received CEE alone; unopposed CEE caused endometrial hyperplasia in PEPI.[4][11]
• Perimenopausal contraception — women with POI can maintain unpredictable ovarian function and should not be presumed infertile; contraceptive needs must be considered alongside HRT.[13][9]
• Little evidence on the optimal type, regimen and dose — in POI, patient preference for route and method of administration of each HRT component must be considered when prescribing.[9]
• Refractory GSM — for bothersome genitourinary symptoms not relieved with over-the-counter therapies, options include low-dose vaginal oestrogen, vaginal dehydroepiandrosterone and oral ospemifene.[5]

Complications & Pitfalls

Risks of combined HRT — the WHI absolute numbers. In the WHI oestrogen-plus-progestin trial (CEE 0.625 mg plus MPA 2.5 mg daily, stopped after a mean 5.2 years), absolute excess risks per 10,000 person-years were 7 more coronary heart disease events, 8 more strokes, 8 more pulmonary emboli and 8 more invasive breast cancers, against 6 fewer colorectal cancers and 5 fewer hip fractures; the global index showed 19 excess events per 10,000 person-years.[3] In the 13-year cumulative follow-up, most risks and benefits dissipated post-intervention, but the breast-cancer elevation persisted (HR 1.28); other CEE-plus-MPA risks included stroke, pulmonary embolism, dementia (in women 65 and over), gallbladder disease and urinary incontinence, and benefits included fewer hip fractures, less diabetes and fewer vasomotor symptoms.[4] For CEE alone in hysterectomised women, coronary disease was not increased (HR 0.91 in the 2004 trial; HR 0.94 with cumulative follow-up), breast cancer trended lower (HR 0.77 in 2004; HR 0.79 cumulatively) and hip fracture fell (HR 0.61, with 6 fewer hip fractures per 10,000 person-years), though stroke was increased (HR 1.39, 12 excess strokes per 10,000 person-years).[21][4] Absolute global-index harm rose steeply with age at initiation — 12 excess cases per 10,000 annually at 50–59 rising to 38 at 70–79 with CEE-plus-MPA, versus 19 fewer cases at 50–59 with CEE alone.[4]

[1]

Why oral oestrogen has higher VTE risk than transdermal — the first-pass hepatic effect reduces antithrombin III and increases factor VII and fibrinogen, tipping the balance toward thrombosis. Transdermal oestrogen bypasses the first pass and does not activate coagulation — the safer route when any VTE or cardiovascular risk factor is present.[4]

Classic pitfalls — assuming amenorrhoea is menopause without excluding pregnancy; relying on a single FSH in the perimenopause (it fluctuates); missing POI in a young amenorrhoeic woman; ignoring postmenopausal bleeding; giving unopposed oestrogen to a woman with a uterus; using the COCP as HRT in POI (the COCP is acceptable but physiological HRT is preferred for long-term replacement); chasing a "low oestradiol" to titrate HRT dose (it should not be used this way). [1]

Endometrial surveillance on HRT — investigate any unscheduled bleeding (transvaginal US, biopsy, hysteroscopy). Routine surveillance of asymptomatic women on HRT is not recommended and does not improve outcomes. [1]

Prognosis & Disposition

Vasomotor symptoms spontaneously resolve in most women within 4 to 7 years; 10 to 15 percent have symptoms for over a decade. The genitourinary syndrome, in contrast, worsens without treatment. Long-term outlook is shaped by age at menopause, lifestyle, bone mineral density, and cardiovascular risk-factor control. [1]

Duration of HRT is individualised — review annually; taper or stop when symptoms resolve (typically 2 to 5 years), but there is no mandatory stop-date for a woman doing well, and the decision balances symptom control against the small duration-dependent breast-cancer risk. [1]

Disposition — most menopausal women are managed in primary care. Refer to a specialist menopause clinic for POI / early menopause, contraindications (breast cancer, VTE), persistent or refractory symptoms, surgical / iatrogenic menopause, and complex hormonal scenarios. [1]

Safety-net — review at 3 months (efficacy and tolerability), annually thereafter (blood pressure, weight, breast awareness, ongoing need), and urgently for any unscheduled or postmenopausal bleeding, chest pain, calf pain, breathlessness, or a sudden severe headache. [1]

Special Populations

Premature ovarian insufficiency (POI, under 40)

POI is the most important special population because the consequences of untreated hypoestrogenism act over a longer horizon and because the standard HRT risk calculus does not apply. POI is defined as a loss of ovarian activity before the age of 40, characterised by irregular or absent periods and reduced fertility; symptoms include those of the natural menopause (night sweats and vaginal dryness) together with the long-term adverse effects of oestrogen deficiency — osteoporosis and cardiovascular disease — believed to explain the shorter life expectancy associated with POI.[9] HRT is strongly recommended, mainly for vasomotor and genito-urinary symptom relief, with a demonstrated role in bone protection and probable primary prevention of cardiovascular disease.[9] Physiological replacement of oestrogen (and progesterone) is essential, and the controversies that surround the use of HRT in postmenopausal women do not apply; there is little evidence on the optimal type, regimen and dose, so patient preference for route and method of each component must be considered, as should contraceptive needs — spontaneous ovulation may still occur.[9][13] The ESHRE guideline structures care with dedicated recommendations on diagnosis and assessment, on the sequelae of POI and their monitoring, and on hormone replacement therapy.[10]

Breast cancer survivors

Women with oestrogen-dependent cancers are among those who are not good candidates for hormone therapy, for whom evidence-based non-hormone treatment is the pathway.[15] The ladder: (i) lifestyle measures; (ii) cognitive-behavioural therapy and clinical hypnosis (Level I); (iii) SSRIs/SNRIs, gabapentin and fezolinetant (Level I) or oxybutynin (Levels I–II); weight loss and stellate ganglion block carry Levels II–III support; clonidine is not recommended.[15] Critical caveat in tamoxifen users: endoxifen is generated by CYP2D6, and paroxetine and fluoxetine (and tricyclic antidepressants) are strong CYP2D6 inhibitors that can blunt tamoxifen's oncologic protection — venlafaxine, escitalopram, citalopram and desvenlafaxine are recommended instead.[25] Breast-cancer treatment increases the prevalence of vulvovaginal atrophy, and local oestrogen in this group remains controversial — an oncology-led decision.[12]

Personal history of VTE or thrombophilia

A personal history of VTE (or a known thrombophilia) is a contraindication to oral oestrogen because the first-pass hepatic effect lowers antithrombin III and raises clotting factors. Transdermal oestrogen bypasses the first pass and does not activate coagulation — so it is the preferred route after haematology input, with the uterus protected by a progestogen (preferably the levonorgestrel IUS, which avoids any additional systemic procoagulant effect). In a woman at high thrombotic risk (e.g. antithrombin deficiency, antiphospholipid syndrome, recent VTE, active malignancy), avoid systemic oestrogen entirely and use non-hormonal options plus vaginal oestrogen for GSM. Always anticoagulate as the primary disease demands; HRT is an adjunct, not a substitute.[4]

Migraine with aura and cardiovascular disease

Migraine with aura is itself a risk factor for ischaemic stroke and is a relative contraindication to oral combined hormonal contraception; the same first-pass logic applies to oral oestrogen in HRT. Transdermal oestradiol avoids the prothrombotic effect and does not appear to increase stroke or VTE risk — it is the route of choice in a woman with migraine with aura, established cardiovascular disease, or multiple vascular risk factors. The same logic applies in women with hypertriglyceridaemia (oral oestrogen can precipitate pancreatitis), gallstones, and uncontrolled hypertension — switch to transdermal and manage the underlying condition.[4]

After hysterectomy — and the endometriosis caveat

A woman who has had a hysterectomy needs oestrogen alone — no progestogen is required because there is no endometrium to protect, and removing the progestogen removes its mood and vascular side-effects. The one exception is a woman with a history of endometriosis who has had a hysterectomy but retains residual endometriotic deposits: add a progestogen (or use tibolone) for a period to suppress any residual disease and avoid the rare but serious complication of malignant transformation of residual endometriosis under unopposed oestrogen. Surgical menopause (bilateral oophorectomy) at any age produces abrupt, severe symptoms and higher long-term bone and cardiovascular risk — start HRT immediately after surgery (unless contraindicated) and continue until the average age of menopause.[5]

Perimenopausal contraception — the often-missed rule

HRT does not suppress ovulation, and a perimenopausal woman can still conceive. Continue a separate contraceptive method until she is definitively postmenopausal — two years of amenorrhoea before age 50 or one year of amenorrhoea after age 50. The combined oral contraceptive pill can be used off-label until age 50 in non-smokers without contraindications; it controls cycle irregularity, provides vasomotor relief, and offers contraception. The levonorgestrel IUS (Mirena) is an excellent dual-purpose option that provides the progestogen component of HRT, controls heavy menstrual bleeding, and offers contraception for up to 5 to 8 years. Sterilisation and barrier methods remain valid throughout the transition. Fertility declines sharply in the late transition but is never zero until the menopause is confirmed.[5]

Obesity

Obesity independently increases VTE risk and worsens vasomotor symptoms (the "insulation" plus altered thermoregulation effect). Oral oestrogen adds a further prothrombotic increment, so the transdermal route is preferred in a woman with a BMI over 30. Weight management is itself a symptomatic and cardiovascular intervention. Vaginal oestrogen can be added for GSM without systemic concerns.[4]

Evidence, Guidelines & Regional Differences

The Women's Health Initiative (WHI, 2002) reported that combined conjugated equine oestrogen plus medroxyprogesterone acetate increased breast cancer, VTE, stroke and coronary events in largely older postmenopausal women, leading to a dramatic global fall in HRT use.[3] Subsequent age-stratified re-analysis (and the 13-year extended follow-up, Manson 2013) showed the excess cardiovascular risk applied principally to women starting over 60 or more than 10 years past menopause.[4]

The 'timing hypothesis' — supported by the Nurses' Health Study, the WHI age-stratified re-analysis, and the KEEPS and ELITE trials — holds that HRT initiated within 10 years of menopause or under age 60 has a neutral or favourable cardiovascular profile, slowing early atherogenesis.[4][5]

The landmark trials — what each showed and what it changed

The evidence base for menopausal hormone therapy is one of the most contested in modern medicine. A candidate who can name the trial, state its population, and summarise its finding will out-perform one who recites a slogan. The trials below are the canon. [1]

The narrative these trials tell. Early observational data (Nurses' Health Study, E3N) suggested that HRT was cardioprotective, prompting HERS and WHI to test this in trials. HERS showed no benefit and early harm in women with established coronary disease; WHI extended that to a broader population of older postmenopausal women and showed the now-familiar risk pattern. The 2013 extended follow-up, plus KEEPS and ELITE, reframed the question: when HRT is started close to the menopause, the cardiovascular profile is neutral or favourable; when started late, in a woman with established (but subclinical) atherosclerosis, it can destabilise plaque and cause events. The Cochrane meta-analysis formalised this as the timing hypothesis. Meanwhile, the breast-cancer signal was always stronger with combined therapy (especially MPA) than with oestrogen-alone, and the E3N cohort suggested that modern oestrogen-plus-micronised-progesterone may carry little or no excess breast-cancer risk — though definitive confirmatory RCT data are still awaited.[3][4][6]

NICE NG23 (2015, updated 2019) — the UK standard

The NICE menopause guideline was commissioned specifically because women were being denied effective treatment on the basis of a misreading of WHI. Its headline messages: diagnose menopause clinically in women over 45 (no FSH needed); offer HRT for vasomotor symptoms after an individualised risk-benefit discussion; consider HRT for POI and continue to the average age of menopause; offer cognitive behavioural therapy for vasomotor symptoms and for low mood; offer vaginal oestrogen for GSM and consider continuing it long-term; do not use compounded bioidentical hormones; explain the VTE and breast-cancer risks and that transdermal oestrogen lowers the VTE risk.[5]

Where evidence is weak or controversial — the effect of HRT on cognitive decline and dementia (the WHI Memory Study suggested harm in older starters, but the question is unresolved in younger women); the long-term breast cancer risk of modern micronised-progesterone regimens (thought to be lower than MPA, but definitive data are awaited); and the role of vaginal laser therapy for GSM (emerging, randomised data limited). [1]

Complementary and alternative therapies — what works and what doesn't

Many women ask about "natural" alternatives. A candidate should know the evidence (or its absence) for each. [1]

Oestrogen deficiency and bone — the silent thief

Postmenopausal osteoporosis is the most clinically important long-term consequence of oestrogen deficiency. Osteoporosis affects 10.2% of adults over 50 (projected to reach 13.6% by 2030) and is diagnosed at a T-score of −2.5 or less or by the presence of a fragility fracture; DXA screening should be considered for all women 65 years and older and for postmenopausal women with clinical risk factors.[18] Therapy is stratified by fracture risk: high risk → antiresorptive therapy (bisphosphonates or denosumab); very high risk or previous vertebral fracture → anabolic agents (teriparatide, abaloparatide or romosozumab) — all on a foundation of weight-bearing exercise, smoking cessation, moderation of alcohol intake, and calcium and vitamin D supplementation.[18] Guideline care further stratifies patients into high-risk and very-high-risk categories and sequences therapy and treatment transitions accordingly.[19] Hormone therapy has been shown to prevent bone loss and fracture in postmenopausal women.[5]

Communication and counselling — the OSCE station

Menopause is a common communication OSCE. The marking domains reward shared decision-making, exploration of the patient's concerns, a balanced presentation of risks and benefits, and a safety-net — not a monologue about the HPA axis. [1]

A counselling framework. (i) Explore — what are her symptoms, their impact on sleep, work, mood, relationships, libido? What does she already know or believe about HRT? What are her priorities (symptom relief, bone, avoiding breast-cancer risk, fertility, contraception)? (ii) Explain the diagnosis — menopause is a clinical diagnosis; her symptoms are real and treatable, not "just getting older". (iii) Present the options — lifestyle for all; HRT (most effective) for symptomatic women under 60 / within 10 years of menopause with no contraindication; non-hormonal alternatives; vaginal oestrogen for GSM. (iv) Discuss risks honestly — VTE (oral more than transdermal), breast cancer (small excess with combined therapy after about 5 years; not with oestrogen-alone), stroke; frame in absolute terms ("a few extra events per 1000 women per year") and contrast with the background risk. (v) Agree a plan — start at a standard dose, review at 3 months, annual review thereafter, with a clear safety-net for unscheduled bleeding, calf pain, chest pain or severe headache. (vi) Check understanding and invite questions. (vii) Provide written information and a follow-up appointment. [1]

Embedded practice — quick-test questions

Use <Reveal> to self-test on the highest-yield discriminators before reading the answer. [1]

A 36-year-old amenorrhoeic woman has a raised FSH on initial testing. What is the diagnosis to exclude, and what must you do next?

[13]

Premature ovarian insufficiency (POI) — loss of ovarian activity before age 40, with irregular or absent periods and reduced fertility — is the working diagnosis once pregnancy has been excluded.[13][9] The structured work-up is history, examination, a pregnancy test and serum LH, FSH, prolactin and TSH.[13] She should not be presumed infertile — POI can maintain unpredictable ovarian function, so contraceptive needs are considered alongside counselling.[13] Start HRT — strongly recommended for vasomotor and genito-urinary relief, bone protection and probable primary prevention of cardiovascular disease; the controversies that surround postmenopausal HRT do not apply to this physiological replacement.[9] [10]

A breast-cancer survivor on tamoxifen has severe flushes. Which SSRI is contraindicated and why?

Paroxetine (and to a lesser extent fluoxetine) — they are potent CYP2D6 inhibitors, and CYP2D6 is the enzyme that converts tamoxifen to its active metabolite endoxifen. Inhibiting it reduces tamoxifen's anti-cancer efficacy. Use venlafaxine or escitalopram instead, both of which have evidence for vasomotor symptoms and minimal CYP2D6 inhibition. Avoid systemic oestrogen entirely in this patient. [1]

A 53-year-old on continuous combined HRT has one episode of bleeding 4 months in. Do you investigate?

Yes — but the bar to investigate rises after 6 months. Light irregular spotting in the first 3 to 6 months of continuous combined therapy is common and acceptable as the endometrium adjusts. Persistent or heavy bleeding, or any bleeding after 6 months, must be investigated exactly like postmenopausal bleeding: examine (speculum and bimanual), transvaginal ultrasound, endometrial biopsy if thickness over 4 to 5 mm, hysteroscopy if sampling inadequate or bleeding recurrent. Never assume unscheduled bleeding is "just the HRT" until endometrial pathology is excluded. [1]

Exam Pearls

• Definition — permanent cessation of menses reflecting oocyte depletion and loss of gonadal steroids, preceded by a transition of wide hormonal fluctuations and irregular cycles.[1]
• POI — loss of ovarian activity before 40; HRT strongly recommended; the postmenopausal-HRT controversies do not apply.[9]
• Uterus rule — with an intact uterus, oestrogen is combined with a progestogen (PEPI: cyclic micronised progesterone 200 mg, cyclic MPA 10 mg, continuous MPA 2.5 mg); unopposed CEE caused hyperplasia in 27.7% vs 0.8% placebo.[11]
• Timing — benefit-risk is favourable under 60 years or within 10 years of menopause onset; less favourable beyond.[5]
• WHI timing re-analysis — CHD HR 0.76 when started within 10 years of menopause vs 1.28 at 20 or more years; stroke elevated regardless.[22] In ELITE, oral oestradiol 1 mg slowed CIMT progression when started within 6 years of menopause but not at 10 or more.[23]
• Abnormal bleeding — endometrial biopsy for women 35 or over with recurrent anovulation, younger women with risk factors, or bleeding unresponsive to medical therapy; atypical hyperplasia or carcinoma → specialist referral.[14]
• Route — hormone-therapy risks differ by route of administration, dose, duration, timing and progestogen; breast-cancer risk did not differ oral vs transdermal in E3N.[5][17]
• Tamoxifen interaction — avoid paroxetine and fluoxetine (strong CYP2D6 inhibitors); use venlafaxine, escitalopram, citalopram or desvenlafaxine.[25]
• WHI 2002 — CEE 0.625 mg plus MPA 2.5 mg in women 50–79: excess of 7 CHD events, 8 strokes, 8 pulmonary emboli and 8 invasive breast cancers per 10,000 women-years; oestrogen-alone did not increase CHD and showed lower cumulative breast cancer (HR 0.79) in hysterectomised women.[3][4]
• VMS duration — frequent vasomotor symptoms lasted a median 7.4 years overall and over 11.8 years when onset was premenopausal — counsel accordingly.[8]
• Non-hormonal therapy — CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin and fezolinetant recommended; clonidine and pregabalin not recommended.[15]

Exam application bank (NEET-PG / INICET)

One-line answer

Menopause is the permanent cessation of menstruation, defined retrospectively as 12 months of amenorrhoea without any other cause (average age 50 to 52; premature ovarian insufficiency before 40). It results from depletion of ovarian follicles producing loss of oestradiol and inhibin, so FSH and LH rise. Symptoms cluster into vasomotor (hot flushes, night sweats — over 75 percent), the genitourinary syndrome of menopause (vaginal dryness, dyspareunia, urinary symptoms) and psychological / sleep disturbance. Long-term oestrogen deficiency drives osteoporosis, cardiovascular disease and urogenital atrophy. Diagnosis is clinical in women over 45; measure FSH only if under 45, after hysterectomy, suspected POI, or atypical. Treatment is individualised HRT — oestrogen (most effective for vasomotor, bone and GSM) plus a progestogen if the uterus is intact (unopposed oestrogen causes endometria

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard. [1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes. [1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change. [1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. [1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory. [1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Menopause & Hormone Replacement Therapy.

References

1. [1]Santoro N, Roeca C, Peters BA, et al. The Menopause Transition: Signs, Symptoms, and Management Options J Clin Endocrinol Metab, 2021.PMID 33095879
2. [2]Cameron CR, Cohen S, Sewell K, et al. The Art of Hormone Replacement Therapy (HRT) in Menopause Management J Pharm Pract, 2024.PMID 37002679
3. [3]Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial JAMA, 2002.PMID 12117397
4. [4]Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials JAMA, 2013.PMID 24084921
5. [5]The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society Menopause, 2022.PMID 35797481
6. [6]Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Cochrane corner: long-term hormone therapy for perimenopausal and postmenopausal women Heart, 2018.PMID 28739806
7. [7]Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging J Clin Endocrinol Metab, 2012.PMID 22344196
8. [8]Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition JAMA Intern Med, 2015.PMID 25686030
9. [9]Webber L, Anderson RA, Davies M, et al. HRT for women with premature ovarian insufficiency: a comprehensive review Hum Reprod Open, 2017.PMID 30895225
10. [10]European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI; Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with premature ovarian insufficiency Hum Reprod, 2016.PMID 27008889
11. [11]The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial JAMA, 1996.PMID 8569016
12. [12]Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy Mayo Clin Proc, 2010.PMID 20042564
13. [13]Klein DA, Poth MA. Amenorrhea: an approach to diagnosis and management Am Fam Physician, 2013.PMID 23939500
14. [14]Sweet MG, Schmidt-Dalton TA, Weiss PM, Madsen KP. Evaluation and management of abnormal uterine bleeding in premenopausal women Am Fam Physician, 2012.PMID 22230306
15. [15]The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. The 2023 nonhormone therapy position statement of The North American Menopause Society Menopause, 2023.PMID 37252752
16. [16]Castrejón-Delgado L, Castelán-Martínez OD, Clark P, et al. Effect of Tibolone on Bone Mineral Density in Postmenopausal Women: Systematic Review and Meta-Analysis Biology (Basel), 2021.PMID 33802101
17. [17]Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study Breast Cancer Res Treat, 2008.PMID 17333341
18. [18]Harris K, Zagar CA, Lawrence KV. Osteoporosis: Common Questions and Answers Am Fam Physician, 2023.PMID 36920813
19. [19]Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update Executive Summary Endocr Pract, 2020.PMID 32427525
20. [20]Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women J Sex Med, 2021.PMID 33814355
21. [21]Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA, 2004.PMID 15082697
22. [22]Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause JAMA, 2007.PMID 17405972
23. [23]Hodis HN, Mack WJ, Henderson VW, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol N Engl J Med, 2016.PMID 27028912
24. [24]Morga A, Ajmera M, Gao E, et al. Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause Menopause, 2024.PMID 38016166
25. [25]Irarrázaval ME, Gaete GL. Antidepressants agents in breast cancer patients using tamoxifen: review of basic and clinical evidence Rev Med Chil, 2016.PMID 28074989